221 related articles for article (PubMed ID: 29880805)
1. Pharmacological inactivation of the PI3K p110δ prevents breast tumour progression by targeting cancer cells and macrophages.
Goulielmaki E; Bermudez-Brito M; Andreou M; Tzenaki N; Tzardi M; de Bree E; Tsentelierou E; Makrigiannakis A; Papakonstanti EA
Cell Death Dis; 2018 Jun; 9(6):678. PubMed ID: 29880805
[TBL] [Abstract][Full Text] [Related]
2. High levels of p110δ PI3K expression in solid tumor cells suppress PTEN activity, generating cellular sensitivity to p110δ inhibitors through PTEN activation.
Tzenaki N; Andreou M; Stratigi K; Vergetaki A; Makrigiannakis A; Vanhaesebroeck B; Papakonstanti EA
FASEB J; 2012 Jun; 26(6):2498-508. PubMed ID: 22391131
[TBL] [Abstract][Full Text] [Related]
3. p110δ PI3K as a therapeutic target of solid tumours.
Xenou L; Papakonstanti EA
Clin Sci (Lond); 2020 Jun; 134(12):1377-1397. PubMed ID: 32556179
[TBL] [Abstract][Full Text] [Related]
4. Inactivation of PI3Kδ induces vascular injury and promotes aneurysm development by upregulating the AP-1/MMP-12 pathway in macrophages.
Zheng L; Xing L; Zeng C; Wu T; Gui Y; Li W; Lan T; Yang Y; Gu Q; Qi C; Zhang Q; Tang F; He X; Wang L
Arterioscler Thromb Vasc Biol; 2015 Feb; 35(2):368-77. PubMed ID: 25503990
[TBL] [Abstract][Full Text] [Related]
5. The p110delta isoform of PI 3-kinase negatively controls RhoA and PTEN.
Papakonstanti EA; Ridley AJ; Vanhaesebroeck B
EMBO J; 2007 Jul; 26(13):3050-61. PubMed ID: 17581634
[TBL] [Abstract][Full Text] [Related]
6. Altered macrophage function contributes to colitis in mice defective in the phosphoinositide-3 kinase subunit p110δ.
Uno JK; Rao KN; Matsuoka K; Sheikh SZ; Kobayashi T; Li F; Steinbach EC; Sepulveda AR; Vanhaesebroeck B; Sartor RB; Plevy SE
Gastroenterology; 2010 Nov; 139(5):1642-53, 1653.e1-6. PubMed ID: 20637203
[TBL] [Abstract][Full Text] [Related]
7. Distinct roles of class IA PI3K isoforms in primary and immortalised macrophages.
Papakonstanti EA; Zwaenepoel O; Bilancio A; Burns E; Nock GE; Houseman B; Shokat K; Ridley AJ; Vanhaesebroeck B
J Cell Sci; 2008 Dec; 121(Pt 24):4124-33. PubMed ID: 19033389
[TBL] [Abstract][Full Text] [Related]
8. Deficiency of p110δ isoform of the phosphoinositide 3 kinase leads to enhanced resistance to Leishmania donovani.
Khadem F; Mou Z; Liu D; Varikuti S; Satoskar A; Uzonna JE
PLoS Negl Trop Dis; 2014 Jun; 8(6):e2951. PubMed ID: 24945303
[TBL] [Abstract][Full Text] [Related]
9. Selective inhibition of phosphoinositide 3-kinase p110α preserves lymphocyte function.
So L; Yea SS; Oak JS; Lu M; Manmadhan A; Ke QH; Janes MR; Kessler LV; Kucharski JM; Li LS; Martin MB; Ren P; Jessen KA; Liu Y; Rommel C; Fruman DA
J Biol Chem; 2013 Feb; 288(8):5718-31. PubMed ID: 23275335
[TBL] [Abstract][Full Text] [Related]
10. Combined Inhibition of Both p110α and p110β Isoforms of Phosphatidylinositol 3-Kinase Is Required for Sustained Therapeutic Effect in PTEN-Deficient, ER
Hosford SR; Dillon LM; Bouley SJ; Rosati R; Yang W; Chen VS; Demidenko E; Morra RP; Miller TW
Clin Cancer Res; 2017 Jun; 23(11):2795-2805. PubMed ID: 27903677
[No Abstract] [Full Text] [Related]
11. Class IA Phosphatidylinositol 3-Kinase Isoform p110α Mediates Vascular Remodeling.
Vantler M; Jesus J; Leppänen O; Scherner M; Berghausen EM; Mustafov L; Chen X; Kramer T; Zierden M; Gerhardt M; Ten Freyhaus H; Blaschke F; Sterner-Kock A; Baldus S; Zhao JJ; Rosenkranz S
Arterioscler Thromb Vasc Biol; 2015 Jun; 35(6):1434-44. PubMed ID: 25908763
[TBL] [Abstract][Full Text] [Related]
12. Specific inhibition of PI3K p110δ inhibits CSF-1-induced macrophage spreading and invasive capacity.
Mouchemore KA; Sampaio NG; Murrey MW; Stanley ER; Lannutti BJ; Pixley FJ
FEBS J; 2013 Nov; 280(21):5228-36. PubMed ID: 23648053
[TBL] [Abstract][Full Text] [Related]
13. The p110δ subunit of PI3K regulates bone marrow-derived eosinophil trafficking and airway eosinophilia in allergen-challenged mice.
Kang BN; Ha SG; Ge XN; Reza Hosseinkhani M; Bahaie NS; Greenberg Y; Blumenthal MN; Puri KD; Rao SP; Sriramarao P
Am J Physiol Lung Cell Mol Physiol; 2012 Jun; 302(11):L1179-91. PubMed ID: 22427531
[TBL] [Abstract][Full Text] [Related]
14. The PI3-kinase isoform p110δ is essential for cell transformation induced by the D816V mutant of c-Kit in a lipid-kinase-independent manner.
Sun J; Mohlin S; Lundby A; Kazi JU; Hellman U; Påhlman S; Olsen JV; Rönnstrand L
Oncogene; 2014 Nov; 33(46):5360-9. PubMed ID: 24213578
[TBL] [Abstract][Full Text] [Related]
15. A combined opposite targeting of p110δ PI3K and RhoA abrogates skin cancer.
Tzenaki N; Xenou L; Goulielmaki E; Tsapara A; Voudouri I; Antoniou A; Valianatos G; Tzardi M; De Bree E; Berdiaki A; Makrigiannakis A; Papakonstanti EA
Commun Biol; 2024 Jan; 7(1):26. PubMed ID: 38182748
[TBL] [Abstract][Full Text] [Related]
16. A selective inhibitor of the p110delta isoform of PI 3-kinase inhibits AML cell proliferation and survival and increases the cytotoxic effects of VP16.
Billottet C; Grandage VL; Gale RE; Quattropani A; Rommel C; Vanhaesebroeck B; Khwaja A
Oncogene; 2006 Oct; 25(50):6648-59. PubMed ID: 16702948
[TBL] [Abstract][Full Text] [Related]
17. PI3K p110δ is expressed by gp38(-)CD31(+) and gp38(+)CD31(+) spleen stromal cells and regulates their CCL19, CCL21, and LTβR mRNA levels.
Zotes TM; Spada R; Mulens V; Pérez-Yagüe S; Sorzano CO; Okkenhaug K; Carrera AC; Barber DF
PLoS One; 2013; 8(8):e72960. PubMed ID: 24009720
[TBL] [Abstract][Full Text] [Related]
18. PI3K p110δ uniquely promotes gain-of-function Shp2-induced GM-CSF hypersensitivity in a model of JMML.
Goodwin CB; Li XJ; Mali RS; Chan G; Kang M; Liu Z; Vanhaesebroeck B; Neel BG; Loh ML; Lannutti BJ; Kapur R; Chan RJ
Blood; 2014 May; 123(18):2838-42. PubMed ID: 24553178
[TBL] [Abstract][Full Text] [Related]
19. Addition of the p110α inhibitor BYL719 overcomes targeted therapy resistance in cells from Her2-positive-PTEN-loss breast cancer.
Zhang C; Xu B; Liu P
Tumour Biol; 2016 Nov; 37(11):14831-14839. PubMed ID: 27639383
[TBL] [Abstract][Full Text] [Related]
20. Genetic or pharmaceutical blockade of phosphoinositide 3-kinase p110δ prevents chronic rejection of heart allografts.
Ying H; Fu H; Rose ML; McCormack AM; Sarathchandra P; Okkenhaug K; Marelli-Berg FM
PLoS One; 2012; 7(3):e32892. PubMed ID: 22479345
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
